Double Labeling Immunofluorescence using Antibodies from the Same Species to Study Host-Pathogen Interactions
July 10th, 2021
7.2K views
Here, the protocol describes how to perform double labeling immunofluorescence using primary antibodies raised in the same species to study host-pathogen interactions. Also, it can include the third antibody from a different host in this protocol. This approach can be made in any cell type and pathogens.
Overview
This article presents a detailed protocol for performing double and triple labeling immunofluorescence using polyclonal and monoclonal antibodies raised in the same species. The method is particularly valuable for studying host cell and pathogen interactions, especially when commercial antibodies are limited or unavailable for specific parasite proteins. The protocol is demonstrated using Trypanosoma cruzi-infected LLC-MK2 cells and provides strategies to prevent cross-reactivity between antibodies.
Key Study Components
Area of Science
- Cell biology
- Immunofluorescence microscopy
- Parasitology
Background
- Commercial antibodies for parasite proteins are scarce, especially for trypanosomatids.
- Polyclonal antibodies are often prepared in-house, which can complicate multiplex labeling when antibodies are from the same species.
- Double or triple labeling is essential for visualizing multiple proteins or structures within host-pathogen systems.
- Preventing cross-reactivity between antibodies of the same species is a technical challenge.
Purpose of Study
- To demonstrate a protocol enabling the use of two or more antibodies from the same host species in immunofluorescence assays.
- To facilitate the study of host-pathogen interactions when antibody resources are limited.
- To provide a cost-effective and adaptable method for protein localization studies in infected cells.
Methods Used
- Infection of LLC-MK2 cells with Trypanosoma cruzi and preparation of infected samples.
- Sequential incubation with mouse polyclonal and monoclonal antibodies, separated by a critical blocking step using AffiniPure rabbit anti-mouse IgG.
- Use of secondary antibodies conjugated to different fluorochromes for distinct labeling.
- Triple labeling by introducing a third antibody from a different species (e.g., rabbit), with appropriate secondary antibodies and blocking steps.
- Staining of nuclei with DAPI and actin filaments with phalloidin-Alexa 594.
- Confocal microscopy for imaging and analysis of labeled samples.
Main Results
- The protocol enables successful double and triple labeling without cross-reactivity between antibodies from the same species.
- Specific localization of parasite and host proteins was achieved: anti-T. cruzi FAZ antibody labeled the parasite flagellum attachment zone, while anti-hnRNP A1 labeled host cell nuclei only.
- DAPI and phalloidin staining confirmed the specificity and integrity of the labeling.
- Confocal images demonstrated clear distinction between host and parasite structures, validating the method's effectiveness.
Conclusions
- This protocol allows for flexible and reliable immunofluorescence labeling when antibody sources are limited.
- The method is adaptable to various cell types and antibody combinations.
- It provides a cost-effective solution for studying protein localization in host-pathogen systems.
Frequently Asked Questions
Why is this protocol important for parasite research?
It addresses the scarcity of commercial antibodies for parasite proteins, enabling researchers to study host-pathogen interactions using available in-house antibodies.
How does the protocol prevent cross-reactivity between antibodies from the same species?
A critical blocking step with AffiniPure rabbit anti-mouse IgG is used between primary antibody incubations to prevent the second secondary antibody from binding to the first primary antibody.
Can this protocol be adapted for triple labeling?
Yes, by introducing a third antibody from a different species and using appropriate secondary antibodies and blocking steps, triple labeling is achievable.
What types of samples can be analyzed with this method?
The protocol is demonstrated with Trypanosoma cruzi-infected LLC-MK2 cells but can be adapted to other cell types and organisms where antibody resources are limited.
What imaging techniques are used to analyze the results?
Confocal microscopy with a 63X oil immersion objective is used to acquire high-resolution images of the labeled samples.
How are nuclei and actin filaments visualized in this protocol?
Nuclei are stained with DAPI, and actin filaments are labeled with phalloidin conjugated to Alexa 594, allowing for clear visualization alongside antibody labeling.
Is this protocol cost-effective compared to commercial antibody solutions?
Yes, it enables the use of in-house antibodies and flexible combinations, reducing reliance on expensive commercial reagents.
Executive Industry Relevance
Double labeling immunofluorescence using antibodies from the same species addresses a critical bottleneck in host-pathogen research where commercial antibody availability is limited, especially for parasite targets. This protocol enables multiplexed protein localization in infected cells, supporting mechanistic de-risking and target validation in early discovery. Its adaptability and cost-effectiveness make it a valuable asset for biopharma teams working with rare or in-house antibody resources.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of host-pathogen interactions when commercial antibodies are scarce.
- Supports functional target validation by allowing simultaneous detection of host and pathogen proteins.
- Facilitates mechanistic de-risking by clarifying protein localization in complex infection models.
Screening & Assay Development
- Prepares validated biological systems for downstream screening workflows by enabling multiplexed labeling.
- Improves assay reproducibility and standardization through defined blocking and detection steps.
- Supports reliable quantitative imaging outputs for compound evaluation in infection models.
Translational & Preclinical Research
- Aligns with disease-relevant systems by enabling protein localization studies in infected host cells.
- Provides continuity from discovery to preclinical validation by supporting flexible antibody combinations.
- Reduces biological risk in translational studies where antibody resources are limited.
Pipeline & Workflow Integration
This protocol integrates into the discovery continuum from early mechanistic studies to preclinical model validation, particularly where antibody supply is a constraint.
- Discovery Biology: Supports hypothesis testing and pathway clarification in host-pathogen systems.
- Screening: Delivers reproducible, multiplexed assay readiness for infection models.
- Analytics: Provides quantitative, channel-separated imaging outputs for comparative analysis.
- Translational Research: Enables biomarker alignment and continuity in disease-relevant infection models.
- Enterprise Reuse: Offers a reusable workflow adaptable to various cell types and antibody sources.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in host-pathogen studies.
- Operational Value: Standardizes multiplex immunofluorescence with limited antibody resources.
- Strategic Value: Improves go/no-go decisions by enabling robust target validation in challenging systems.
- Portfolio Impact: Supports risk-adjusted prioritization where commercial reagents are unavailable.
Implementation Considerations
- Requires expertise in immunofluorescence and confocal microscopy.
- Needs access to high-quality imaging infrastructure and validated secondary antibodies.
- Demands rigorous blocking and washing steps to prevent cross-reactivity.
- Adaptable across different cell types and infection models with limited antibody sources.
- Dependent on careful antibody selection and subclass compatibility for multiplexing.
Biopharma FAQs
Why does null hypothesis testing matter for double labeling immunofluorescence?
Null hypothesis testing ensures that observed protein localization differences in host-pathogen systems are statistically significant and not due to random variation or cross-reactivity. This is critical for validating mechanistic insights and supporting target confidence in early discovery.
How does independent variable isolation fit the antibody blocking procedure?
Isolating the effect of each antibody through sequential incubation and specific blocking steps allows clear attribution of each fluorescent signal to its target. This isolation is essential for accurate interpretation and downstream decision-making in discovery workflows.
What do quantitative dependent variable measurements enable in confocal imaging?
Quantitative measurements of fluorescence intensity and localization enable objective comparison of protein distribution between infected and non-infected cells. These outputs support robust data analysis and cross-condition validation in R&D pipelines.
Why are replication requirements important for cross-functional collaboration?
Replication ensures that double labeling results are reproducible across experiments and teams, facilitating reliable data sharing and integration in multi-disciplinary biopharma projects. This underpins confidence in mechanistic findings and portfolio decisions.
What statistical analysis capabilities are required before implementing this immunofluorescence protocol?
Teams must be equipped to perform statistical comparisons of fluorescence data, assess specificity, and validate the absence of cross-reactivity. These capabilities are necessary to ensure data integrity and support actionable insights in the discovery pipeline.
Chapters in this video
0:04
Introduction
1:21
Parasite Cultures
2:00
Control Immunofluorescence Protocol
3:23
Double Labeling Immunofluorescence ProtocolUsing Monoclonal and Polyclonal Antibodies Raised in the Same Host
4:18
Triple Labeling Immunofluorescence Protocol with the Addition of the Third Polyclonal Antibody from Different Host Species
5:16
Confocal Imaging Acquisition
5:39
Results: Host-pathogen Interactions Studies Using Double Labeling Immunofluorescence
6:51
Conclusion
